Welcome to CDC Stacks | Prescription of Pneumocystis jiroveci pneumonia prophylaxis in HIV-infected patients - 44256 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Prescription of Pneumocystis jiroveci pneumonia prophylaxis in HIV-infected patients
  • Published Date:
    Sep 14 2016
  • Source:
    J Int Assoc Provid AIDS Care. 15(6):455-458.


Public Access Version Available on: November 01, 2017 information icon
Please check back on the date listed above.
Details:
  • Pubmed ID:
    27629868
  • Pubmed Central ID:
    PMC5310212
  • Description:
    The US treatment guidelines recommend Pneumocystis jiroveci pneumonia (PCP) prophylaxis for all HIV-infected persons with a CD4 count <200 cells/mm(3) (ie, eligible for PCP prophylaxis). However, some studies suggest PCP prophylaxis may be unnecessary in virally suppressed patients. Using national data of HIV-infected adults receiving medical care in the United States during 2009 to 2012, the authors assessed the weighted percentage of eligible patients who were prescribed PCP prophylaxis and the independent association between PCP prophylaxis prescription and viral suppression. Overall, 81% of eligible patients were prescribed PCP prophylaxis. Virally suppressed eligible patients were less likely to be prescribed PCP prophylaxis (prevalence ratio: 0.84; 95% confidence interval: 0.80-0.89). Although guidelines recommend PCP prophylaxis for all eligible patients, some HIV care providers might not prescribe PCP prophylaxis to virally suppressed patients. Additional data on the risk for PCP among virally suppressed patients are needed to clarify this controversy.

  • Document Type:
  • Collection(s):
  • Funding:
    CC999999/Intramural CDC HHS/United States
  • Supporting Files:
    No Additional Files
No Related Documents.
You May Also Like: